CAIHealthcare · BiotechnologyCAI Stock Forecast: Caris Life Sciences, Inc. Price Predictions for 2026-2027
The 13 Wall Street analysts covering Caris Life Sciences, Inc. hold a median 12-month price target of $27 — +65.4% from the last close. Ticker Nerd's systematic factor model, run across ~4,600 US stocks, ranks it 30 of 100 as at 1 Aug 2026 — in the lower half. The Street sees upside; the factor read is a caution. That gap is the story on this page.
CAI stock analysis: one number for the whole business
Consensus tells you what everyone already believes. The model scores Caris Life Sciences, Inc. on its factor families — the same systematic rank behind the Ticker Nerd portfolio.
Percentile across ~4,600 US stocks on Ticker Nerd’s systematic factor model. Higher is better. How the model is built and tested
Value (77): The shares cost little relative to the profits and assets behind them — which can mean the market is too gloomy, or that the business really is in trouble.
Momentum (10): The shares have been drifting down relative to others.
The rank is the raw material. Whether the rules would actually own Caris Life Sciences, Inc. — and when they’d sell — is the membership.
CAI stock forecast 2026-2027: analyst price targets & predictions
The bullish and bearish analyst opinions on CAI, reported as data — targets and ratings, the market's view beside the model's.
Price targets and ratings are third-party analyst estimates, reported here as data. They are not Ticker Nerd forecasts, and they are frequently wrong.
The green dot is the last close — the median target sits +65.4% from it.
| Date | Firm | Action | Rating | Target |
|---|---|---|---|---|
| 6 July 2026 | Evercore ISI Group | Maintains | Outperform | $30 → $25 |
| 2 July 2026 | BTIG | Reiterates | Buy | $32 |
| 2 June 2026 | Wolfe Research | Assumes | Peer Perform | — |
| 8 May 2026 | BTIG | Maintains | Buy | — |
| 8 May 2026 | Citigroup | Maintains | Buy | — |
| 8 May 2026 | JP Morgan | Maintains | Overweight | — |
| 13 Apr 2026 | Jefferies | Initiates | Buy | — |
| 10 Apr 2026 | Piper Sandler | Initiates | Neutral | — |
| 6 Apr 2026 | Evercore ISI Group | Maintains | Outperform | — |
| 13 Mar 2026 | Canaccord Genuity | Maintains | Hold | — |
| 27 Feb 2026 | Baird | Maintains | Outperform | — |
| 27 Feb 2026 | BTIG | Maintains | Buy | — |
| 27 Feb 2026 | Evercore ISI Group | Maintains | Outperform | — |
| 17 Feb 2026 | Baird | Initiates | Outperform | — |
| 22 Dec 2025 | Canaccord Genuity | Maintains | Hold | — |
| 2 Dec 2025 | Canaccord Genuity | Initiates | Hold | — |
| 13 Aug 2025 | Citigroup | Maintains | Buy | — |
| 13 Aug 2025 | Evercore ISI Group | Maintains | Outperform | — |
| 13 Aug 2025 | Guggenheim | Maintains | Buy | — |
| 15 July 2025 | Evercore ISI Group | Initiates | Outperform | — |
Price targets and ratings are third-party analyst estimates, reported here as data. They are not Ticker Nerd forecasts, and they are frequently wrong.
CAI analyst estimate revisions
Not the forecast itself — the direction analysts are revising it. Revision direction is one of the model's factor families.
Caris Life Sciences, Inc. (CAI) financial data
A margin means little on its own. Each bar marks where the figure sits across the whole US universe we score.
- Trailing P/E
- 7.6×
- Price / sales
- 4.9×
- Price / book
- 7.5×
- EV / EBITDA
- 31.3×
Cheaper than 63% of US stocks
Cheaper than 25% of US stocks
Cheaper than 14% of US stocks
Cheaper than 9% of US stocks
- Revenue growth (YoY)
- 78.8%
- Earnings growth (YoY)
- 78.8%
- Gross margin
- 65.4%
- Operating margin
- 2.4%
- Net margin
- 3.7%
Higher than 92% of US stocks
Higher than 83% of US stocks
Higher than 80% of US stocks
Higher than 52% of US stocks
Higher than 57% of US stocks
- Return on equity
- 28.4%
- Return on assets
- 9.3%
- Dividend yield
- —
Higher than 87% of US stocks
Higher than 91% of US stocks
Bars mark the percentile across the ~4,600 US stocks Ticker Nerd covers, among those reporting the figure.
CAI vs competitors
The nearest names by industry and size, scored by the same model — like for like.
This page is one stock. Monday covers all of them.
Computed off the Friday close and sent before the US open.
Market Radar reports the week’s largest rank changes across roughly 4,600 US stocks, the factor behind each one, and where the market went. CAI appears on the weeks it earns a place.
Frequently asked questions about CAI stock
What is the CAI stock price forecast for 2026-2027?
The 13 Wall Street analysts covering Caris Life Sciences, Inc. have a median 12-month price target of $27, with estimates ranging from $21 to $36. These are third-party analyst estimates, not Ticker Nerd forecasts, and they are frequently wrong.
Is CAI stock a buy right now?
Of the 13 analysts covering Caris Life Sciences, Inc., 10 rate it a Buy, 3 a Hold and 0 a Sell. Ticker Nerd's systematic factor model ranks Caris Life Sciences, Inc. 30 out of 100 across roughly 4,600 US stocks as at 1 Aug 2026. None of this is personal advice — it does not consider your circumstances.
How does Ticker Nerd's model rank CAI?
As at 1 Aug 2026, Caris Life Sciences, Inc. ranks 30 out of 100 on Ticker Nerd's systematic factor model — a percentile across roughly 4,600 US stocks, built from its factor families. Its strongest factor family is Value (77 of 100).
Will CAI stock go up?
No one can know that. What the data says: the median 12-month target from 13 analysts implies +65.4% from the last close, and Ticker Nerd's factor model ranks Caris Life Sciences, Inc. 30 out of 100 as at 1 Aug 2026. Analyst targets are third-party estimates and frequently wrong; none of this is personal advice.
What is the CAI stock forecast for 2030?
No analyst covering Caris Life Sciences, Inc. publishes a 2030 price target — Wall Street targets run 12 to 18 months out. Sites quoting a 2030 price for CAI are extrapolating price history, which says nothing about the business. The furthest attributed numbers are the current analyst targets: $21 to $36 over the next 12 months.
How has CAI stock performed over the past year?
Caris Life Sciences, Inc. returned -41.8% over the 12 months to 3 Aug 2026, with dividends reinvested. Past performance does not indicate future returns.
What does Caris Life Sciences, Inc. do?
Caris Life Sciences is a leading AI-driven precision medicine company that transforms healthcare through comprehensive molecular profiling and advanced machine learning. The company specializes in analyzing cancer at the molecular level by performing whole exome and whole transcriptome sequencing on patient tissue and blood samples.
About Caris Life Sciences, Inc.
Caris Life Sciences is a leading AI-driven precision medicine company that transforms healthcare through comprehensive molecular profiling and advanced machine learning. The company specializes in analyzing cancer at the molecular level by performing whole exome and whole transcriptome sequencing on patient tissue and blood samples. Its flagship offerings include MI Profile for tissue-based profiling, Caris Assure for blood-based analysis, and Caris Detect, a multi-cancer early detection blood assay leveraging ultra-deep whole genome sequencing. Caris has built one of the world's largest multimodal clinico-genomic databases, combining genomic, transcriptomic, and proteomic data with clinical outcomes from over 740,000 matched patient records. The company serves oncologists and patients by providing molecular information to guide therapy selection, support drug development, and enable early disease detection. Founded in 2008 and headquartered in Irving, Texas, Caris operates internationally with offices across major medical and research hubs, delivering precision medicine solutions that help physicians and patients make informed treatment decisions based on individual tumor biology.
CEO Dr. David Dean Halbert M.D. · 1,846 employees · United States · https://www.carislifesciences.com